Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANTENEH A TESFAYE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1003128810
CMS profile
90675
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$429.37

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $229.43 10
Education $199.94 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANTENEH A TESFAYE

NPI 1003128810 · CMS profile ID 90675

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003128810?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANTENEH A TESFAYE, NPI 1003128810, CMS profile ID 90675. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003128810?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANTENEH A TESFAYE, NPI 1003128810, CMS profile ID 90675. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003128810?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANTENEH A TESFAYE, NPI 1003128810, CMS profile ID 90675, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003128810?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $429.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $31.0712/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015703099 CMS
SERVIER PHARMACEUTICALS LLC $17.3211/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055085125 CMS
Genentech USA, Inc. $28.6710/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040301693 CMS
Incyte Corporation $22.4910/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044504021 CMS
Seagen Inc. $17.5309/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995740757 CMS
Novartis Pharmaceuticals Corporation $17.8108/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993413689 CMS
Amgen Inc. $20.9606/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019810481 CMS
GENZYME CORPORATION $24.2205/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049921453 CMS
Genentech USA, Inc. $25.7505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040301689 CMS
Seagen Inc. $99.9904/21/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995740677 CMS
Seagen Inc. $99.9504/21/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995740683 CMS
Seagen Inc. $23.6103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995740559 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,924.09 3
PY2020 $71.56 4
PY2021 $1,496.54 5
PY2023 $429.37 12
PY2024 $4,800.48 25

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $26,667.00 9
PY2024 Principal investigator $241,753.30 23
PY2023 Recipient $111.26 1
PY2023 Principal investigator $77,142.19 3
PY2021 Principal investigator $7,000.00 3
PY2020 Principal investigator $26,660.00 1
PY2019 Principal investigator $45,209.66 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $3,332.00 06/18/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691333957
Principal investigator 1 Incyte Corporation $70.00 06/17/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458947
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 06/11/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691334631
Principal investigator 1 Merck Sharp & Dohme Corporation $435.20 06/11/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691345397
Principal investigator 1 Incyte Corporation $2,000.00 06/04/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458945
Principal investigator 1 Incyte Corporation $2,000.00 06/04/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458963
Principal investigator 1 Incyte Corporation $1,000.00 06/03/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458957
Principal investigator 1 Merck Sharp & Dohme Corporation $3,332.00 05/02/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691344947
Principal investigator 1 Incyte Corporation $1,000.00 05/01/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458955
Principal investigator 1 Incyte Corporation $2,000.00 04/17/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458941
Principal investigator 1 Incyte Corporation $2,000.00 04/17/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458959
Principal investigator 1 Incyte Corporation $2,000.00 04/17/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458961
Principal investigator 1 Incyte Corporation $459.00 04/16/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458939
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 04/11/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691314313
Principal investigator 1 Merck Sharp & Dohme Corporation $660.00 04/09/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691314017
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 04/09/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691314663
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 04/09/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691536797
Principal investigator 1 Merck Sharp & Dohme Corporation $3,202.00 03/05/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691314669
Principal investigator 1 Merck Sharp & Dohme Corporation $825.00 02/28/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691326487
Principal investigator 1 Incyte Corporation $918.00 02/20/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458927
Principal investigator 1 Incyte Corporation $70.00 02/20/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458929
Principal investigator 1 Merck Sharp & Dohme Corporation $4,474.00 02/19/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691314403
Principal investigator 1 Incyte Corporation $2,000.00 02/13/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458925
Principal investigator 1 Incyte Corporation $2,000.00 02/13/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458931
Principal investigator 1 Incyte Corporation $2,000.00 02/13/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458933
Principal investigator 1 Incyte Corporation $2,000.00 02/13/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458935
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 01/31/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691305619
Principal investigator 1 Merck Sharp & Dohme Corporation $1,820.00 01/29/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691305627
Principal investigator 1 Merck Sharp & Dohme Corporation $27.46 01/17/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase III Study of Pembrolizumab MK-3475 vs. Best Supportive Care as Second-LineTherapy in Subjects with Previously Systemically Treated Advanced HepatocellularCarcinoma KEYNOTE-240 No dispute reported 06/30/2026 691483535
Principal investigator 1 Incyte Corporation $85.00 01/04/2019 Covered Recipient Teaching Hospital
KARMANOS CANCER HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666458923